Chadi Nabhan, Chief Medical Officer and Head of Strategy at Ryght, shared on X:
“Daraxonrasib is approved.
This is a clip from Health care Unfiltered when Dr. Shubham Pant and Tanios Bekaii-Saab, joined the show to review the data originally presented at ASCO26 and later published in NEJM.
A monumental advance to say the least.
Watch the Full Podcast.”
You can also read: FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
